Co-Founder & CEO
John Sherwood, PhD
Neuroscientist and entrepreneur pioneering neurotechnology and organoid electrophysiology to advance research and drug discovery.
Full bio of John SherwoodDon't wait for the clinic to find out
Animal models and generic cells don't reflect the human brain. Too often you only learn a compound fails after years of work and millions spent.
Lead your team into precision drug discovery, without betting the program.
The FDA no longer requires animal testing before human trials, and its 2025 roadmap aims to make animal studies the exception. Brain organoids grown from patients’ own cells are the human alternative. But going first is hard to justify: the lab build-out, the hires, the months before you know if it works.
Run it through Dyalex instead. One experiment, no capital outlay, and the evidence to lead the conversation with your team.
How a pilot works
-
01 · Send your compound
Tell us the question. Start with a single pilot experiment. Your IP stays yours.
-
02 · We run it
On brain organoids grown from patients' own cells, in the Dyalex automated lab. We carry the operational risk.
-
03 · You get the readout
Human-relevant evidence early, so you can push forward or cut losses with confidence.
NIH
Backed by an NIH Fast-Track SBIR award
View grant
Nature
Built on our 2017 work on brain organoids
Read paper
$8.1M
13 years of NIH funding behind the neurotechnology Dyalex builds on
See grants
We run the infrastructure. You own the science.
Dyalex lab services are fee-for-service: your compounds, data and IP stay yours, with no milestones or royalties.
People
The Dyalex team advancing human-relevant drug discovery
Leadership
Co‑Founder & CSO
Giorgia Quadrato, PhD
Pioneering reproducible brain organoid systems with single‑cell omics to decode brain biology and advance transformative therapies.
Full bio of Giorgia QuadratoAdvisors
Scientific Advisor
John Isaac, PhD
Internationally recognized neuroscientist shaping innovation in neurodegeneration and psychiatry across academia, pharma, and biotech.
Full bio of John Isaac
Deeptech Advisor
Andrew Meyer
Experienced deep‑tech founder and board member, CEO of LeafLabs and Pickle Robot, guiding robotics and Physical AI companies toward scalable impact.
Full bio of Andrew Meyer
Venture Advisor
Adam Stein
Founder turned deep-tech investor, CEO of FernBio, with exits in biotech, climate and AI, guiding founders on capital raising and business models.
Full bio of Adam SteinStart with one experiment.
Walk away knowing how your compound behaves in human brain tissue. Investors, we’d love to hear from you too.